Skip to content

Author

Ö. Ölmez

We have 4 of 55 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined....

Ebru Karcı, T. Atasever, Tansel Çakır et al. · 0 citations
Oct 2026

Reconsidering the Value of Baseline PET/CT in Early-Stage Breast Cancer: Evidence for Selective Use from the MF21-02 Multicenter Study

Background: The role of ^18F-FDG PET/CT in the initial staging of early-stage breast cancer remains controversial, as current guidelines discourage its routine use due to the low prevalence of distant metastases. This study aimed to evaluate the diagnostic yield and clinical impact of baseline PET/CT in a large multice...

M. A. Nazlı, O. Toktaş, S. Özbaş et al. · 0 citations
Open access Oct 2026

Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

Purpose Androgen receptor (AR) expression is detectable in the majority of breast cancers across all molecular subtypes; however, its predictive value for pathological complete response (pCR) and its prognostic contribution to long-term survival in an all-comer neoadjuvant chemotherapy (NACT) cohort remain incompletely...

Harun Muğlu, V. B. Erol, H. Özçelik et al. · 0 citations
Open access Sep 2026

Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

Data on the clinicopathological features of NRG1 fusion-positive non-small cell lung cancer (NSCLC) are limited. We conducted a retrospective, multicenter study and included patients with NRG1 fusion-positive NSCLC diagnosed between January 2018 and February 2025. Six patients were identified; five were female (83.3%),...

B. Köylü, N. Genc, M. H. Yücel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.